Format

Send to

Choose Destination
Ann N Y Acad Sci. 2006 Oct;1082:137-50.

CpG oligonucleotides improve the protective immune response induced by the licensed anthrax vaccine.

Author information

1
Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA. Klinman@CBER.FDA.GOV

Abstract

Synthetic oligodeoxynucleotides (ODN) containing unmethylated CpG motifs act as immune adjuvants, improving the response elicited by a coadministered vaccine. Combining CpG ODN with anthrax vaccine adsorbed (AVA, the licensed human vaccine) increases the speed, magnitude, and avidity of the resultant antibody response. IgG Abs against anthrax protective antigen (PA) protect mice, guinuea pigs, and rhesus macaques from infection.

PMID:
17145935
DOI:
10.1196/annals.1348.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center